Literature DB >> 10421438

Association of tetramers of human butyrylcholinesterase is mediated by conserved aromatic residues of the carboxy terminus.

C V Altamirano1, O Lockridge.   

Abstract

Human butyrylcholinesterase (BChE) is composed predominantly of tetramers. Our laboratory has shown that up to 40 carboxy terminal residues of each subunit contribute to the stabilization of tetramers (R.M. Blong, E. Bedows, O. Lockridge, The tetramerization domain of butyrylcholinesterase is at the carboxy-terminus, Biochem. J. 327 (1997) 747-757). To better define the residues which participate in tetramer stabilization, the in vivo interaction of the BChE C-terminus 46 residue peptide was quantitated for wild type and mutant BChE using the yeast two-hybrid system. The wild type C-terminal peptides interacted with one another in this system. The K-variant (A539T) and C571A peptides showed interaction similar to that of the wild type. However, only 11.7% of the interaction seen with the wild type peptide was observed with the mutant in which seven conserved aromatic residues (Trp 543, Phe 547, Trp 550, Tyr 553, Trp 557, Phe 561, and Tyr 564) had been altered to alanines (aromatics off mutant). When these seven mutations were incorporated into the complete BChE molecule and expressed in 293T cells, only monomers and dimers were observed. The addition of poly-L-proline to the medium of 293T cells expressing wild type BChE resulted in the increase of the tetrameric form, similar to that observed by Bon et al. (S. Bon, F. Coussen, J. Massoulié, Quaternary associations of acetylcholinesterase II. The polyproline attachment domain of the collagen tail, J. Biol. Chem. 272 (1997) 3016-3021) for acetylcholinesterase expressed in COS cells. However, no increase in tetramers was observed with poly-L-proline addition to the medium of 293T cells expressing the aromatics off BChE mutant. These observations suggest that the stabilization of BChE tetramers is mediated through the interaction of the seven conserved aromatic residues, Trp 543, Phe 547, Trp 550, Tyr 553, Trp 557, Phe 561, and Tyr 564, and that the poly-L-proline induced increase in tetrameric BChE is mediated through these seven aromatic residues.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10421438     DOI: 10.1016/s0009-2797(99)00013-7

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  15 in total

1.  His-tag truncated butyrylcholinesterase as a useful construct for in vitro characterization of wild-type and variant butyrylcholinesterases.

Authors:  Erik C Ralph; Longkuan Xiang; John R Cashman; Jun Zhang
Journal:  Protein Expr Purif       Date:  2011-07-23       Impact factor: 1.650

2.  Aerosolized recombinant human butyrylcholinesterase delivered by a nebulizer provides long term protection against inhaled paraoxon in macaques.

Authors:  Yvonne Rosenberg; James Fink; Ronan MacLoughlin; Tara Ooms-Konecny; Dennis Sullivan; William Gerk; Lingjun Mao; Xiaoming Jiang; Jonathan Lees; Lori Urban; Narayanan Rajendran
Journal:  Chem Biol Interact       Date:  2019-06-12       Impact factor: 5.192

3.  LARGE SCALE PURIFICATION OF BUTYRYLCHOLINESTERASE FROM HUMAN PLASMA SUITABLE FOR INJECTION INTO MONKEYS; A POTENTIAL NEW THERAPEUTIC FOR PROTECTION AGAINST COCAINE AND NERVE AGENT TOXICITY.

Authors:  Oksana Lockridge; Lawrence M Schopfer; Gail Winger; James H Woods
Journal:  J Med Chem Biol Radiol Def       Date:  2005-07-01

4.  Pharmacophore-based virtual screening and density functional theory approach to identifying novel butyrylcholinesterase inhibitors.

Authors:  Sugunadevi Sakkiah; Keun Woo Lee
Journal:  Acta Pharmacol Sin       Date:  2012-06-11       Impact factor: 6.150

5.  Crystallization and X-ray structure of full-length recombinant human butyrylcholinesterase.

Authors:  Michelle N Ngamelue; Kohei Homma; Oksana Lockridge; Oluwatoyin A Asojo
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2007-08-10

6.  Characterization of butyrylcholinesterase from porcine milk.

Authors:  Ashima Saxena; Tatyana Belinskaya; Lawrence M Schopfer; Oksana Lockridge
Journal:  Arch Biochem Biophys       Date:  2018-06-15       Impact factor: 4.013

7.  Recombinant human butyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoning.

Authors:  Yue-Jin Huang; Yue Huang; Hernan Baldassarre; Bin Wang; Anthoula Lazaris; Martin Leduc; Annie S Bilodeau; Annie Bellemare; Mélanie Côté; Peter Herskovits; Madjid Touati; Carl Turcotte; Loredana Valeanu; Nicolas Lemée; Harvey Wilgus; Isabelle Bégin; Bhim Bhatia; Khalid Rao; Nathalie Neveu; Eric Brochu; Janice Pierson; Duncan K Hockley; Douglas M Cerasoli; David E Lenz; Costas N Karatzas; Solomon Langermann
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-27       Impact factor: 11.205

8.  Visualization of exogenous delivery of nanoformulated butyrylcholinesterase to the central nervous system.

Authors:  Andrea Gaydess; Ellen Duysen; Yuan Li; Vladimir Gilman; Alexander Kabanov; Oksana Lockridge; Tatiana Bronich
Journal:  Chem Biol Interact       Date:  2010-01-11       Impact factor: 5.192

9.  An albumin-butyrylcholinesterase for cocaine toxicity and addiction: catalytic and pharmacokinetic properties.

Authors:  Yang Gao; David LaFleur; Rutul Shah; Qinghai Zhao; Mallika Singh; Stephen Brimijoin
Journal:  Chem Biol Interact       Date:  2008-05-01       Impact factor: 5.192

10.  The butyrylcholinesterase K variant confers structurally derived risks for Alzheimer pathology.

Authors:  Erez Podoly; Deborah E Shalev; Shani Shenhar-Tsarfaty; Estelle R Bennett; Einor Ben Assayag; Harvey Wilgus; Oded Livnah; Hermona Soreq
Journal:  J Biol Chem       Date:  2009-04-21       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.